A Molecular Pathway-based Umbrella Trial for First-line Precision Therapy With TROP2 in Patients With Locally Advanced or Metastatic TNBC (Future-Trop2 Study)
Latest Information Update: 07 Jul 2023
At a glance
- Drugs Camrelizumab (Primary) ; Fuzuloparib (Primary) ; Rezvilutamide (Primary) ; Sacituzumab govitecan (Primary)
- Indications Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms FUTURE-Trop2
Most Recent Events
- 07 Jul 2023 New trial record